These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28154815)

  • 1. The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery.
    Karawajczyk A; Orrling KM; de Vlieger JS; Rijnders T; Tzalis D
    Front Med (Lausanne); 2016; 3():75. PubMed ID: 28154815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
    Honarnejad S; van Boeckel S; van den Hurk H; van Helden S
    SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Lead Factory: An updated HTS compound library for innovative drug discovery.
    van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB
    Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory.
    Morgentin R; Dow M; Aimon A; Karageorgis G; Kalliokoski T; Roche D; Marsden S; Nelson A
    Drug Discov Today; 2018 Sep; 23(9):1578-1583. PubMed ID: 29753124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.
    Karawajczyk A; Giordanetto F; Benningshof J; Hamza D; Kalliokoski T; Pouwer K; Morgentin R; Nelson A; Müller G; Piechot A; Tzalis D
    Drug Discov Today; 2015 Nov; 20(11):1310-6. PubMed ID: 26429298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Innovative Medicines Initiative: Progress to Date.
    Faure JE; Dyląg T; Norstedt I; Matthiessen L
    Pharmaceut Med; 2018; 32(4):243-249. PubMed ID: 30174434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective.
    Rainard JM; Pandarakalam GC; McElroy SP
    SLAS Discov; 2018 Mar; 23(3):225-241. PubMed ID: 29460707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The innovative medicines initiative: a public private partnership model to foster drug discovery.
    Vaudano E
    Comput Struct Biotechnol J; 2013; 6():e201303017. PubMed ID: 24688725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development.
    Davis AM; Engkvist O; Fairclough RJ; Feierberg I; Freeman A; Iyer P
    SLAS Discov; 2021 Jun; 26(5):604-619. PubMed ID: 33586501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public-private partnerships as driving forces in the quest for innovative medicines.
    Goldman M; Compton C; Mittleman BB
    Clin Transl Med; 2013 Jan; 2(1):2. PubMed ID: 23369569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.
    Laverty H; Meulien P
    Front Med (Lausanne); 2019; 6():275. PubMed ID: 31850354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena.
    Paillard G; Cochrane P; Jones PS; van Hoorn WP; Caracoti A; van Vlijmen H; Pannifer AD
    Drug Discov Today; 2016 Jan; 21(1):97-102. PubMed ID: 26608890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Joint European Compound Library: boosting precompetitive research.
    Besnard J; Jones PS; Hopkins AL; Pannifer AD
    Drug Discov Today; 2015 Feb; 20(2):181-6. PubMed ID: 25205347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participating in innovative medicines initiative funded neurodegenerative disorder projects-An impact analysis conducted as part of the NEURONET project.
    Hawksworth C; Salih F; Cresswell K; Steukers L; Diaz C; Killin L; Pradier L; Bradshaw A; Dawoud D
    Front Neurol; 2023; 14():1140722. PubMed ID: 37006486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Chinese drug discovery research: impact of hit and lead identification.
    Zhou C; Zhou Y; Wang J; Zhu Y; Deng J; Wang MW
    J Biomol Screen; 2015 Mar; 20(3):318-29. PubMed ID: 25520370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.